Jean-Pierre Gotteland

Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs

Oliver Pohl, Simon Coates, Jean-Pierre Gotteland, 2019, Therapeutic innovation & regulatory science.

(Aryloxy)methylsilane Derivatives as New Cholesterol Biosynthesis Inhibitors: Synthesis and Hypocholesterolemic Activity of a New Class of Squalene Epoxidase Inhibitors.

Jean-Pierre Gotteland, Serge Halazy, Isabelle Brunel, 1995 .

AS601245 (1,3-Benzothiazol-2-yl (2-{[2-(3-pyridinyl) ethyl] amino}-4 pyrimidinyl) Acetonitrile): A c-Jun NH2-Terminal Protein Kinase Inhibitor with Neuroprotective Properties

Jean-Pierre Gotteland, P. Vitte, A. Hiver, 2004, Journal of Pharmacology and Experimental Therapeutics.

Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase.

Jean-Pierre Gotteland, Anthony Nichols, Serge Halazy, 2005, Journal of medicinal chemistry.

c-Jun NH2-terminal kinase inhibitor bentamapimod reduces induced endometriosis in baboons: an assessor-blind placebo-controlled randomized study.

Jean-Pierre Gotteland, S. Palmer, C. Kyama, 2016, Fertility and sterility.